Factor IX complex for the correction of traumatic coagulopathy.

Area of Science:

• Trauma surgery
• Emergency medicine
• Hematology

Background:

• Damage control resuscitation emphasizes coagulopathy correction, but options are limited and costly.
• Prothrombin complex concentrate (PCC), or factor IX complex, offers a rapid, cost-effective solution for coagulopathy reversal.
• This study details the experience with PCC in coagulopathic trauma patients.

Purpose of the Study:

• To describe the clinical experience with factor IX complex (PCC) in trauma patients.
• To evaluate the efficacy of PCC in treating coagulopathy and reversing anticoagulation.
• To assess the impact of PCC on blood product transfusion requirements.

Main Methods:

• Retrospective review of 45 trauma patients who received PCC over a two-year period.
• PCC administered at the discretion of trauma attending for coagulopathy or coumadin reversal.
• Analysis of international normalized ratio (INR) and packed red blood cell (PRBC) transfusion data pre- and post-PCC.

Main Results:

• PCC administration significantly decreased mean INR (p = 0.001) in all trauma patients.
• Packed red blood cell transfusion was reduced post-PCC (p = 0.018).
• Thromboembolic events occurred in 7% of patients; mortality was 36%.

Conclusions:

• PCC rapidly and effectively treats acute coagulopathy in trauma patients.
• PCC significantly corrects INR and reduces blood product transfusion needs, regardless of warfarin use.
• PCC is a valuable tool for managing acute coagulopathy of trauma, warranting further investigation.